<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430053</url>
  </required_header>
  <id_info>
    <org_study_id>040081</org_study_id>
    <secondary_id>04-C-0081</secondary_id>
    <secondary_id>CDR0000354510</secondary_id>
    <nct_id>NCT00430053</nct_id>
    <nct_alias>NCT00075322</nct_alias>
  </id_info>
  <brief_title>Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma</brief_title>
  <official_title>Pathogenesis And Course Of Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about patients with cutaneous T-cell lymphoma over time may&#xD;
      help doctors learn more about the disease.&#xD;
&#xD;
      PURPOSE: This natural history study is collecting disease-related health information over&#xD;
      time from patients with cutaneous T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Follow the disease course of patients with cutaneous T-cell lymphoma.&#xD;
&#xD;
        -  Provide a patient population for study by proteomic and molecular analysis.&#xD;
&#xD;
        -  Develop a mechanism for screening by a Tumor Board for enrollment of patients in&#xD;
           therapeutic clinical trials.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Develop a tissue bank for future disease study using specimens from these patients.&#xD;
&#xD;
        -  Provide community outreach by offering a second opinion regarding treatment of this&#xD;
           disease in these patients and, in limited cases, provide standard-of-care treatment to&#xD;
           these patients.&#xD;
&#xD;
        -  Develop an algorithm for screening and evaluating this disease in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo disease assessment by physical examination, full-body photographic&#xD;
      documentation of skin disease, biopsy, and blood sampling at baseline and then at least&#xD;
      annually thereafter. Proteomic and molecular methods are used to analyze samples. Biopsies&#xD;
      may be examined using histologic and immunohistochemical methods. Blood may be analyzed by&#xD;
      polymerase chain reaction for clonal T-cell gene rearrangements or by flow cytometry.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Disease course of patients with cutaneous T-cell lymphoma (CTCL)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Provide a patient population for study by proteomic and molecular analysis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mechanism for screening by a Tumor Board for enrollment of patients in therapeutic clinical trials</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Develop a tissue bank for future disease study</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Offer a second opinion regarding treatment of CTCL and, in limited cases, provide standard-of-care treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Develop an algorithm for screening and evaluating CTCL</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene rearrangement analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Histologically confirmed stage IA-IVB cutaneous T-cell lymphoma (CTCL) (mycosis&#xD;
                  fungoides or Sézary syndrome)&#xD;
&#xD;
               -  Other histologically and clinically confirmed primary or secondary CTCL&#xD;
&#xD;
               -  Histologically and clinically confirmed pre-CTCL skin condition, including large&#xD;
                  plaque parapsoriasis and lymphomatoid papulosis&#xD;
&#xD;
          -  Measurable disease by skin lesion assessment or Sézary cell count&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Human T-cell lymphotrophic virus (HTLV) I/II negative&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark C. Udey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Dermatology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

